FDA: Pfizer’s COVID-19 coronavirus vaccine 95% effective
FDA: Pfizer’s COVID-19 coronavirus vaccine 95% effective. On Sunday (6th) Eastern time, U.S. Department of Health and Human Services (HHS) Secretary Alex Azar sent optimistic news about the timetable for the first launch of the COVID-19 vaccine in the United States. He said that if the US Food and Drug Administration (FDA) hearing goes smoothly, the COVID-19 vaccine can be approved within a few days at the earliest.
“If everything is normal and the advisory committee is going well, I believe we can see the FDA approval within a few days,” Alex Azar mentioned in an interview with the media on Sunday when he mentioned the hearing on Pfizer’s vaccine this Thursday. But it will follow the FDA’s gold standard process… and I will make sure it does this.”
FDA: Pfizer’s new coronavirus vaccine is 95% effective in preventing the new coronavirus
The FDA will review the Pfizer vaccine this week and review the Moderna vaccine on December 17, after the two companies claimed that their COVID-19 vaccine is more than 90% effective.
This means that the United States is expected to become the second country after the United Kingdom to officially approve vaccine marketing. According to the British government last Wednesday (2nd), the government has approved the use of Pfizer and BioNTech’s COVID-19 vaccine. The vaccine will be available throughout the UK starting this week.
However, the United Kingdom approved Pfizer’s COVID-19 vaccine too hastily, and it was bombarded by EU officials. They accused the British health authorities of putting speed above safety and urged other EU countries not to repeat this ultra-fast process.
When the media interviewed Alex Azar on Sunday, they were worried about whether the United States would follow the British steps after the FDA hearing. He responded, “I will ensure the independence and integrity of decision-making… He is willing to follow the opinions of FDA professional scientists.”
The Centers for Disease Control and Prevention (CDC) team recommended last week that initial vaccination should be targeted at healthcare workers and critically ill patients. As for ordinary people, Alex Azar pointed out that in February or March next year, it should be widely spread.
“We will gradually cover more and more people,” Alex Azar said. “By the second quarter of next year, we will have enough vaccines to meet every American in need.”
The current U.S. epidemic continues to worsen. Not only has the number of new diagnoses hit a new high of nearly 228,000 (last Friday), the number of deaths has also exceeded the March high, and the number of hospitalizations and ICUs has increased rapidly. Medical resources are under pressure.